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Abstract
Human CD4+ T cells process and present functional class II MHC-peptide complexes, but the endogenous peptide repertoire
of these non-classical antigen presenting cells remains unknown. We eluted and sequenced HLA-DR-bound self-peptides
presented by CD4+ T cells in order to compare the T cell-derived peptide repertoire to sequences derived from genetically
identical B cells. We identified several novel epitopes derived from the T cell-specific proteome, including fragments of CD4
and IL-2. While these data confirm that T cells can present peptides derived from the T-cell specific proteome, the vast
majority of peptides sequenced after elution from MHC were derived from the common proteome. From this pool, we
identified several identical peptide epitopes in the T and B cell repertoire derived from common endogenous proteins as
well as novel endogenous epitopes with promiscuous binding. These findings indicate that the endogenous HLA-DR-bound
peptide repertoire, regardless of APC type and across MHC isotype, is largely derived from the same pool of self-protein.
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Introduction
Endogenous peptides presented via class II MHC bind the T
cell receptor (TCR) to regulate CD4+ T cell development,
homeostasis, and activation in the periphery [1]. These peptides
represent the majority of MHC-bound ligands displayed by
antigen presenting cells (APC) [2] and are derived from a wide
variety of endogenous proteins in a diversity of APC-specific
stimulatory microenvironments [3].
Common among the APC subtypes are self-peptides presented
in course as a byproduct of class II MHC processing. These
include the invariant chain (Ii; CD74) chaperone fragment CLIP,
which occludes the MHC binding pocket during assembly [4,5].
Peripheral APC can regulate CLIP expression at the cell surface
[6], [7]. Up-regulation of CLIP in tandem with antigenic peptide
presentation in activated dendritic cells has been shown to
enhance Th1-type cytokine secretion in antigen-specific T cell
responders [6]. Although CLIP is the only known non-antigenic
self-peptide to elicit a polar shift in the quality of the CD4+ T cell
response, several groups have reported that self-peptide MHC
complexes at the immune synapse stabilize antigenic peptide-TCR
interactions and strengthen activating signals [8,9].
In the absence of antigenic stimuli, endogenous presentation by
peripheral APC induces weak, non-specific signaling in CD4+ T
cells that lowers the threshold of activation in naı¨ve cells [10] and
preserves memory cell functionality [11]. A number of these self-
peptides, however, act as antigenic epitopes themselves; endoge-
nous presentation is sufficient to activate peripheral CD4+ T cells
with high-affinity for self-peptide:MHC complexes. Aberrant
activation of self-reactive T cells contributes to autoimmune
diseases such as multiple sclerosis and type 1 diabetes [12,13].
Modulation of endogenous antigen presentation in the periphery
reduces self-reactivity and prevents the development of autoim-
mune pathogenesis [14]. Self-antigen specific regulatory CD4+ T
cells (Treg) also control peripheral immune activation by locally
suppressing proliferation and cytokine secretion [15]. Therefore
both inflammatory and suppressive reactions can be generated by
APC through the regulation of self-peptide generation and
presentation to self-specific CD4+ T cells.
Although APC do express common self-peptides [16], cell-type
specific differences in proteome and lysosomal protease activity
can generate unique peptide-MHC repertoires [17]. This is most
apparent in thymic epithelial cells, where transcriptional regula-
tion of the cellular proteome results in unique self-peptide
expression and presentation that is functionally exploited during
thymic selection [18]. In this manner, the cell-type specific
proteome is sampled to generate the class II MHC peptide
repertoire, and presentation of these tissue-specific peptides
dictates APC function.
The relationship between self-peptide identity and APC
function may prove to be particularity informative in the case of
class II MHC+ CD4+ T cells. These non-professional APC are
thought to present self-peptide exclusively unless loaded with
soluble peptide or infected by tropic viruses [19,20]. The APC
function of class II MHC+ CD4+ T cells remains largely unknown,
although several studies have suggested that these cells induce
TCR-specific anergy [21]. Indeed, endogenous expression of
HSP60 by CD4+ T cells has been shown to increase presentation
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of an HSP60-derived epitope that stimulates HSP60-specific
immunosuppression [22]. Cell-type specific presentation of self-
antigen in the periphery may therefore have the potential to elicit
regulatory responses.
Here, we isolate and identify HLA-DR-bound self-peptides
expressed by activated CD4+ T cell clones which constitutively
express class II MHC. In order to determine the contribution of
the cell-type specific proteome to the MHC-bound peptide
repertoire, we compared these T cell-derived peptides to HLA-
DR-bound peptides isolated from donor-matched B cells. We
identified several cell-type specific peptides uniquely expressed and
presented by T cells or B cells, including fragments of CD4 and
IL-2 and of the B cell receptor heavy and light chains, respectively.
Yet despite these cell-type specific differences, we found that the
MHC-bound endogenous peptide repertoire was largely shared
between T cells and B cells. Both APC types predominately
expressed peptides derived from the common proteome. Common
peptides presented by these APC had similar frequency of
expression, HLA-DR isotype affinity, and, in many cases, identical
core sequences. Among these shared sequences, we identified
several novel endogenous epitopes. Furthermore, when we
compared sequences derived from two donors with unique
MHC haplotypes, we found that many of the same proteins and
peptide sequences were represented in the peptide repertoire of
each. These findings indicate that while the cellular proteome does
contribute to unique self-peptide presentation, endogenous peptide
expression is promiscuous and largely shared amongst APC.
Materials and Methods
Cell culture reagents and antibodies
All cells were cultured in RPMI 1640 medium supplemented with
2 mM L-glutamine, 5 mM HEPES, 100 U/ml penicillin/strepto-
mycin (all from BioWhittaker), 0.5 mM sodium pyruvate, 0.5 mM
nonessential amino acids (from Life Technologies) in 25 cm2 vented
flasks (CoStar). The media for T cell clones was further
supplemented with 5% human AB serum (Mediatech) and 25 U/
ml recombinant human IL-2 (Tecin, National Cancer Institute). The
media for B cell lines was supplemented with 10% FBS.
The anti- CD3 (UCHT1), CD4 (RPA-T4), CD28 (CD28.2 and
3D10), class I MHC (G46-2.6), class II MHC (Tu¨39), HLA-DR
(L243), HLA-DP (B7.21), HLA-DQ (Tu¨169), and isotype control
monoclonal antibodies were purchased from BD Pharmingen. The
monoclonal antibody Tu¨36, recognizing HLA-DRab dimers [23],
was purified from hybridoma by Cell Essentials (Boston, MA).
Generation of CD4+ T cell clones and EBV transformed B
cell lines
Ethics statement. The use of human samples for this study
was approved by the Brigham and Women’s Hospital Institutional
Research Board (IRB).
T cell clones and B cell lines were generated from the peripheral
blood of healthy individuals after informed and written consent, as
previously described [7]. Briefly, whole mononuclear cells (PBMC)
were isolated by Ficoll-Hypaque (GE Healthcare) gradient
centrifugation. CD4+ T cells were isolated using the CD4+ T
cell negative isolation kit II (Miltenyi Biotech) and sorted at one
cell per well into 96-well U-bottom plates containing 26105
irridiated (5000 rad) PBMC, 50 U/ml recombinant Il-2, and
1 mg/ml each anti- CD3 and CD28 (3D10). Clones were
expanded for 4 weeks and then subsequently re-stimulated in
25 cm2 flasks coated with anti- CD3 and CD28. EBV transformed
B cell lines were generated from PBMC as previously described
[24].
Flow cytometry
To confirm purity and expression of class II MHC, T cell clones
and B cell lines were stained with fluorophore-conjugated primary
antibody (at a concentration of 5 mg/ml). Acquisition was done on
a FACScalibur with the CellQuest software (Becton-Dickinson)
and data was analyzed using FloJo (TreeStar).
Mass spectrometry
Cells (107 to 108) were harvested and washed in PBS prior to
lysis in buffer containing 1% Triton X-100. Lysates were
centrifuged at 15,0006g for 15 minutes at 4uC and pre-cleared
once with normal mouse serum and protein A-agarose beads
(Pierce) and once with protein A alone. HLA-DRab complexes
were precipitated with mAb Tu¨36 conjugated to CNBr-activated
Sepharose 4B beads (GE Healthcare). After extensive washing,
peptides were eluted with 0.1% trifluoracetic acid. MALDI
analyses (Waters Micro MX) was used for initial screening of the
eluent prior to further use. Peptides were identified with a Waters
NanoAcquity HPLC system operated in a nanoflow mode using
reversed phase chromatography. The LC system was directly
coupled to a ThermoFisher LTQ linear ion trap mass spectrom-
eter. Analysis was performed using data dependant analysis to
maximize the number of peptides subjected to fragmentation.
MS/MS data were processed and subjected to database searches
using Sequest (ThermoFisher) against the SwissProt databases.
Predictions of peptide binding to HLA-DR were made with
NetMHCII (http://www.cbs.dtu.dk/services/NetMHCII/) [25].
Results
HLA-DR-bound peptide elution from a donor-matched B
cell and T cell
We hypothesized that peripheral APC with unique proteomes
generate different pools of APC-specific endogenous peptides for
presentation via class IIMHC. To test this hypothesis, we developed
two unique APC types from a genetically identical donor; these are
chronically activated CD4+ T cell clones and EBV-transformed B
cell lines. These APC have similar levels of constitutive class II
MHC expression and defined lysosomal protease expression and
activity [7,26]. These APC types also express predominantly self-
peptide and have overlapping proteomes with defined singularities.
We generated and expanded B and T cell APC as described
previously [7]. Chronically activated CD4+ T cell clones acquire
constitutive cell surface class II MHC expression and, like EBV-
transformed B cells, can elicit antigen-specific T cell responses when
loaded with exogenous peptide [19,27]. We expanded individual B
and T cell clones from a single donor and confirmed cell-surface
expression of class II MHC determinants by flow cytometry
(Figure 1A). We found no significant differences in class II MHC
expression between B cell and T cell clones, although the B cells
expressed on average higher levels of both class I and class II MHC.
To determine the endogenous peptide repertoire of these cells,
we eluted peptides from affinity-purified HLA-DR molecules and
performed sequence analysis using liquid chromatography and
nano-electrospray ionization tandem mass spectrometry
(Figure 1B). Peptide preparations subject to MS/MS and peptide
identification were verified for quality using MALDI prior to
further analysis. Peptide elution was performed in triplicate (for T
cells) and duplicate (for B cells) from independent cell cultures
derived from a single clone, and was repeated in two donors. We
confirmed the specificity of our affinity purification by spiking our
lysate with a known peptide prior to immunoprecipitation and
elution (data not shown) and by immunoprecipitation with an
irrelevant antibody (Figure S1).
Class II Self-Antigens in Human B/T Lymphocytes
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In total, we identified 791 peptides comprising 384 unique
sequences from within the combined B and T cell repertoire
(Table 1; Table S1). We found that 2565.3% (average 6 SD) of
the peptides we identified had overlapping sequences and were
found in multiple samples, suggesting a bias toward certain
peptides in HLA-DR binding, or possibly in our identification
protocol. We identified a small number of peptides derived from
serum (1.2% of total peptides), primarily derived from serotrans-
ferrin and serum amyloid P-component (Table S5). While the
majority of epitopes we identified were unique, our findings
included peptide sequences that are known to bind HLA-DR
(DRB1), including sequences from Ii, apolipoprotein B-100,
lysosomal acid lipase/cholesteryl ester hydrolase, HLA-DRa,
HLA-DRa, cathepsin B, lysosomal protective protein, and
phosphoglycerate kinase 1 [6,28,29,30]. We also identified
proteins that are presented via class II MHC in other species,
including the transferrin receptor, Ig m chain, and b-galactosidase
[31,32]. These similarities suggest that certain peptides and
proteins are more frequently represented in the class II MHC
binding pocket than others, regardless of APC type or MHC
haplotype. Furthermore, consistent with previous studies [6,31],
we did not find a bias towards transmembrane or endo/lysosomal
proteins among the most abundant self-peptides in the binding
pool. Taken together, these findings suggest that certain epitopes
are globally favored for class II MHC presentation and may be
targeted specifically for peptide generation and loading.
Endogenous peptides derived from the common
proteome
Of the self-peptides that we identified, a majority was derived
from proteins shared within the common proteome of B and T
Figure 1. Isolation of HLA-DR:self-peptide complexes from an expanded class II MHC positive T cell clone (T cell) and a EBV-
transformed B cell clone from the same donor. A. Characterization of class II MHC, class I MHC, and CD4 expression in a representative
genetically-matched T cell clone and B cell line. B. Strategy used to identify self-peptides. HLA-DR:peptide complexes were immunoprecipitated from
T and B cell lysates. Peptides were eluted from the MHC and assessed for quality and contaminants with MALDI before being subjected to
multidimensional protein sequencing and identification using the SEQUEST algorithm. C. Frequency of common self-peptides identified T and B cells
from a donor 1 (DRB1*1301; DRB1*1501 DRB3*0202; DRB5*0101).
doi:10.1371/journal.pone.0029805.g001
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cells. In a single donor (DRB1*1301/1501; DRB3*0202;
DRB5*0101), 34.41% of peptide sequences with multiple hits
were common to both B and T cells (Table 1). The majority of
these peptides were derived from six proteins—gamma interferon
lysosmal thiol reductase (GILT), HLA-DRa (2DRA), HLA-DQb
(HB25), sortillin-related receptor (SORL1), plastin-2 (PLSL), and
cofilin-1 (COF1)—which represented 21.55% and 32.50% of the
T and B cell peptide repertoire, respectively (Figure 1C).
Although T and B cells largely presented peptides derived from
the same proteins at the same frequency, there was one notable
exception. We found that B cells predominantly presented
peptides derived from HLA-DQb (HB25) (11.9%), while T cells
presented this protein at a significantly lower frequency (0.45%)
(Figure 1C). The same core peptide sequence of HLA-DQB1
was identified in both B cell and T cell samples (DVGVYR-
AVTPQGRPDA; 43–58), so selective use by B cells of a unique
peptide sequence cannot explain this discrepancy. Furthermore,
such biased presentation was not observed for any other proteins
in the shared proteome (Figure 2). The increased frequency of
this HLA-DQb peptide in the B cell repertoire could be a
consequence of greater HLA-DQb protein expression
(Figure 1A); our analysis does not exclude this possibility,
although it is interesting to note that peptides derived from class I
MHC, which is more highly expressed in B cells than T cells, and
HLA-DR or HLA-DP, which both have expression ratios similar
to HLA-DQ, were not represented with greater frequency in the
B cell peptide repertoire.
We identified several endogenous epitopes that were both
shared and abundant in both B and T cells (Table 2; Table S2).
These ‘abundant’ epitopes were classified as peptides containing a
shared sequence that were identified in replicate elutions in both a
B cell and a T cell sample. Peptides encoding an abundant epitope
possessed identical core sequences, each one of which contained
the predicted DRB1 p1 binding residues (Y, F, L, I, V, W)
followed by 9–14 amino acids. Our data confirms previous reports
of epitopes identified from proteins such as HLA-DRa, CD74, and
cathepsin B. Additionally, we identified several unique epitope
sequences derived from HLA-DRB1, b2-microglobulin, and
semaphorin 4D.
Endogenous peptides derived from cell-type specific
proteome
In addition to epitopes derived from common proteins, we
identified several peptide sequences derived from cell-restricted
proteome (Figure 3). From our B cell samples, we identified
known epitopes in proteins such as immunoglobulin m heavy chain
(Figure 3A, Table S1). These findings confirm the specificity of
our elution protocol and confirm previous observations regarding
the capacity for B cells to present tissue-specific proteins [29].
From our T cell derived samples, we identified several novel
peptide epitopes that included abundant, overlapping fragments of
CD4 and IL-2 (Figure 3A). It is likely that these novel epitopes
within CD4 and IL-2 are also presented in cells that express CD4,
such as monocytes; in cells that can bind and utilize IL-2, such as
CD25+ B cells and cd T cells; and in scavenger cells that ingest
and present apoptotic CD4+ T cells. We also identified peptide
sequences, although at a lower frequency, from galectin-1, TGF-b
receptor type III, and BDNF/NT-3 growth factor receptor
(Table S1).
Antigens derived from CD4+ T cells injected as a vaccine can
activate so called antigen-specific idiotypic and ergotypic responses
[33]. HLA-DR+ CD4+ T cells themselves have been hypothesized
to present T cell-derived proteins such as CD25 or HSP60 [22].
Although we did identify an epitope within IL-2 that can be
Table 1. Number and frequency of peptides identified.
Donor 1 Donor 2
HLA-DR haplotype DRB1*1301; DRB1*1501 DRB3*0202; DRB5*0101 DRB1*0101; DRB1*0301 DRB3*0101
total peptides characterized 644 147
# peptide sequences 279 105
peptides sequences with multiple, overlapping hits 82 29.39% 23 21.90%
peptide sequences common to B and T 96 34.41% 4 3.81%
B cell elution
number of cells used for purification 10‘7 10‘7
total peptides characterized 196 109
# peptide sequences 81 82
peptide sequences unique to B cells 48 17.20%a 78 74.28%a
peptide sequences with multiple hits 25 30.86%b 20 24.39%b
# of these peptides unique to B cells 9 11.11%b 18 21.95%b
T cell elution
number of cells used for purification 10‘8 10‘7
total peptides characterized 448 38
# peptide sequences 213 30
peptide sequences unique to T cells 135 48.39%a 26 24.76%a
peptides sequences with multiple hits 57 26.76%b 4 13.33%b
# of these peptides unique to T cells 30 52.63%b 2 50.00%b
a% of total sequences.
b% of cell-type specific sequences.
doi:10.1371/journal.pone.0029805.t001
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considered ‘‘ergotypic’’ (Figure 3A), we were unable to identify
any peptides derived from HSP60 in this assay; although we did
identify peptides derived from heat shock cognate 71 kDa protein
(HSPA8), a ubiquitously expressed chaperone protein. The
possibility remains that T cells do possess the capacity to present
HSP60 or other idiotypes such as TCRab, as the experiments
described here lack the necessary resolution to identify rare
peptide sequences. Immunogenic epitopes are frequently rare and
strong representation in the class II MHC-bound peptide
repertoire is not required to activate a T cell response [34,35].
Overall, we identified very few abundant tissue-specific
peptides. Over 90% of peptides identified from both B and T
cells were derived from within the common proteome (Figure 3B).
These data suggest that APC with constitutive class II MHC
processing largely sample from the same protein pool and
predominantly do not express epitopes derived from cell-type
specific proteome, despite high expression of these unique cell
type-specific proteins.
B and T cells utilize MHC isotypes with the same
frequency
Several of the epitopes identified in our analysis were found in
the binding repertoire of both B and T cells. Given the common
identity of these sequences, we hypothesized that B and T APC
utilize class II MHC isotypes with the same frequency. Our tissue
donor possessed multiple class II MHC alleles, which allowed us to
challenge this hypothesis by comparing epitope-MHC affinity
across the MHC isotypes for peptides isolated from either B cell or
T cell samples.
We used qualitative prediction to generate a matrix of peptide-
MHC binding affinities (Table S3). In order to determine the
binding affinity, we applied the SMM-align method, using default
parameter settings on the NetMHCII webserver [25], to each
replicated peptide sequence identified in our elution. This method
predicted a nine amino acid binding core motif for each MHC
isotype and returned a score for binding (IC50 and nM affinity).
We judged epitopes with affinity scores less than 500 nM as
Figure 2. Total number of peptides identified from common proteins in the T cell and B cell self-presentation repertoire. Experiments
were performed in triplicate (for T cell clones) and in duplicate (for B cell lines) using cells prepared from donor 1 (mean6range).
doi:10.1371/journal.pone.0029805.g002
Table 2. Core sequence of a subset of abundant self-peptides isolated from both T cells and B cells (donor 1).
Protein Protein Name Core Sequence Localization
# Peptides core
sequence Rank
2DRA HLA class II histocompatibility antigen, DR alpha chain EFGRFASFEAQG membrane 15 4
HB2B HLA-class II histocompatibility antigen, DR beta chain FLDRYFYNQEESVRFDS membrane 2 33
HB25 HLA class II histocompatibility antigen, DQ beta chain DVGYRAVTPQGRPDA membrane 25 3
CD74 HLA class II histocompatibility antigen, gamma chain DPSSGLGVTKQDLGPVPM membrane 3 24
B2M Beta-2-microglobulin KSNFLNCYVSGFHPS membrane 2 35
SEM4D Semaphorin-4D NLPDKTLQFVKDHPLMDDS membrane 12 7
APOB Apolipoprotein B-100 QILPWEQNEQVKNFVAS secreted 2 35
CATB Cathepsin B FSVYSDFLLYKSGV lysosomal 4 21
GILT Gamma-interferon-inducible lysosomal thiol reductase FFGNGPPVNYKT lysosomal 42 2
CALR Calreticulin YSPDPSIYAYDNFG cytosolic 10 10
G3P Glyceraldehyde-3-phosphate dehydrogenase ENGKLVINGNPITI cytosolic 11 8
KYDNSLKIISNASCTTN 6 13
GSTP1 Glurathione S-transferase QDGDLTLYQSNTILRH cytosolic 3 25
HSP7C Heat shock cognate 71 kDa protein DAAKNQVAMNPTNTVFDAK cytosolic 10 9
The core sequence represents the largest consensus peptide sequence identified for total nested protein fragments across all samples for a single donor. The total
number of peptides identified for donor 1 that contain each core sequence is indicated. Predicted p1 anchor residues for DRB1 binding are in bold (p1 = Y, F, L, I, V, W).
doi:10.1371/journal.pone.0029805.t002
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potential binders, including in our positive scoring both weak
(,500 nM) and strong (,50 nM) contacts. For epitopes that
contained multiple core motifs, we analyzed all predicted core
motif sequences independently and chose for cumulative analysis
the sequence with the highest predicted affinity for each isotype.
Using this strategy, we broadly surveyed trends in predicted MHC
occupancy using our B cell and T cell derived peptide pools.
We found that predicted class II MHC occupancy was not
significantly different for peptides derived from either B cells or T
cells (Figure 4). Additionally, peptides derived from the APC-
specific proteome showed nearly identical isotype binding
distribution (data not shown). We found that in total, a third of
the peptides we analyzed in all samples scored positive for
predicted binding to DRB1*1501. This data may reflect a greater
representation of DRB1*1501 over the other isotypes precipitated
from our initial lysates.
A significant fraction of peptides we identified, 12.7962.71%
(mean6SD), were predicted to bind more than three MHC
isotypes. This finding suggests that the endogenous peptide pool
may be highly promiscuous in MHC occupancy. A the relatively
large number of amino acids can serve as class II MHC anchor
residues, and degeneracy in self-peptide MHC binding has been
previously reported [36]. We cannot, however, accurately
determine the extent of MHC promiscuity using this analysis
strategy. As our prediction determined that 50% of the peptides
analyzed bound two or more MHC isotypes, it is likely that this
prediction overestimated the extent of degeneracy in MHC
binding. Furthermore, this method does not take into account
flanking residues or alternative, tertiary binding structure, which
can both alter MHC binding affinity [37].
Self-peptide epitopes shared between genetically diverse
donors
We found that B cells and T cells from the same donor sampled
largely from the same proteins, and from these proteins the same
epitopes, for class II MHC presentation. We next sought to
determine whether a unique donor, expressing a different set of
MHC alleles, would sample from that same protein pool for
Figure 3. Self-peptides identified from the cell-type specific proteome include key signaling receptors such as CD3, CD4 and the B
cell receptor. A. Cell-type specific nested peptide sequences isolated from T cells and B cells (donor 1). Predicted core binding sequence is indicated
in yellow. B. Frequency of peptides derived from the common (on non-cell-type specific) proteome and the cell-type specific proteome in T cells and
B cells. Experiments were performed in triplicate (for T cell clones) and in duplicate (for B cell lines) using cells prepared from donor 1 (mean6SD).
doi:10.1371/journal.pone.0029805.g003
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presentation. We repeated our APC generation, HLA-DR
precipitation, and elution in a second donor that did not express
the same set of MHC alleles as the first donor (DRB1*0101, 0301;
DRB3*0101) (Table 1). Like our first sample set, the gross
majority of peptides sequenced were derived from proteins within
the common proteome, although we found fewer sequences in
common between B and T cells in the second donor (Table S4).
We observed a number of peptide sequences in our second
donor that were derived from the same proteins that were
identified in our first donor (Table 3). These included several
sequences derived from proteins such as apolipoprotein B-100, b2-
microglobulin, and semaphorin-4D. The majority of peptides
identified were unique to our second donor, despite their origin
from a common protein substrate.
We also discovered several rare epitopes that shared a peptide
sequence between the two donors. Specifically, we identified
among these novel sequences in glyceraldehyde-3-phospate
dehydrogenase and formin-2 (Table 3). Also among the epitopes
shared between our two donors was a fragment of HLA-DRa
(EFGRFASFEA; 72–81), which was previously identified in an
elution from a homozygous DRB1*1501 cell line [29]. Binding of
this epitope in both of our donors, one of which does not express
DRB1*1501, agreed with our prediction that some endogenous
peptides can bind in a degenerate fashion to multiple of the MHC
isotypes.
Together these findings indicated that the endogenous peptide
repertoire is largely sampled from the common proteome, not only
in B and T APC, but also in donors with unique MHC allelic
expression.
Discussion
We initiated this study to identify APC-specific similarities and
differences in endogenous peptide presentation. Here we describe,
to our knowledge, the largest pool of endogenous peptides
identified to date and the first to elute peptide sequences presented
from HLA-DR+ T cells. CD4+ HLA-DR+ T cells are novel APC
that can generate immunosuppressive rather than activating
signals via class II MHC [21]. One third of the potent regulatory
CD4+ CD25high T cell subset expresses HLA-DR [38], but no
studies to date have identified epitopes within the T cell peptide
repertoire. We discovered several novel epitopes derived from the
T APC specific proteome, including peptides derived from CD4
and IL-2 but no T cell receptor sequences (Figure 3A). Many
groups have hypothesized the nature of peptides presented by T
cells; experimentally predicted epitopes have included fragments of
HSP60 [22]. We did not identify any of these predicted ergotypic
epitopes in our elution set, but cannot exclude the possibility that
the epitopes we identified can elicit an anti-ergotypic response or
that other ergotypic epitopes are presented at the cell surface at a
low frequency. While antigenic epitopes do not need to be
presented at high frequency in order to evoke an immune response
[34,35], we studied the occupation of the majority of HLA-DR
complexes in constitutively class II MHC+ cells and not the
generation of rare antigenic epitopes that may arise as a
consequence of activation or other stimulation event due to the
limited resolution of our elution protocol.
We eluted peptides bound to HLA-DR in two unique APC with
largely overlapping proteomes, B cells and T cells. We found that
in both APC, the class II MHC complexes predominantly sampled
from the shared endogenous proteome and not the tissue-specific
proteome (Figure 3B). Indeed, many of the same proteins and
peptide epitopes that we here describe have been previously
identified in dendritic cell samples with shared allelic expression
[6]. Taken together, these data suggest that all HLA-DR+ APC
possess a similar endogenous peptide repertoire.
While we did not observe many differences in the proteins
presented in terms of epitope identity, we did find a significant
increase in the presentation of a shared epitope, HLA-DQB1 (43–
58). This epitope was represented at a much higher frequency in B
cells than in T cells (Figure 2). This peptide was previously
identified in a peptide elutions using DRB1*1501 B cells [6] and
brain tissue samples from patients with multiple sclerosis [39], and
is highly abundant in the B cell endogenous peptide repertoire.
Why B cells alone selectively express high levels of this peptide
remains to be determined. These APC do possess slightly higher
levels of HLA-DQ expression than T cells, but similarly high levels
expression of other HLA alleles by B cells (Figure 1A) does not
lead to increased representation in the HLA-DR binding pocket.
Exclusive or preferential usage by B cells of the DRB1*1501
isotype could account for this finding, however we did not predict
any differences in MHC utilization between B cells and T cells
(Figure 4). Additionally, selective peptide editing likely does not
contribute to differences in DQB1 (43–58) presentation, as this
Figure 4. Predicted class II MHC occupancy for self-peptides derived from a single donor with multiple MHC alleles. Peptides with
both weak (,500 nM) and strong (,50 nM) predicted affinity are considered as positive for binding. The large frequency of peptides for which no
MHC binding could be predicted or which greater than 3 MHC alleles was predicted suggests the likelihood of MHC promiscuity among self-peptides.
doi:10.1371/journal.pone.0029805.g004
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epitope forms stable complexes with DRB1*1501 (DRB2) that are
not significantly altered by the enzymatic activity of the loading
molecule HLA-DM [40]. The possibility remains that B cells may
possess unique mechanisms to enhance presentation of this peptide
both in vitro and in vivo.
In order to determine the impact of MHC allelic expression on
endogenous proteome presentation, we extended our analysis to
donors with different MHC allelic expression. We found that, even
between two donors with unique MHC alleles, the endogenous
peptide repertoire was largely derived from the same set of
proteins in the common proteome. Most surprisingly, in two
genetically distinct donors we identified identical peptide sequenc-
es presented in the HLA-DR binding pocket (Table 3). Our data
indicates that the bulk of endogenous peptide presentation is
biased towards the presentation of a few self-proteins. The MHC-
bound proteins are sampled from multiple compartments and
include both those that are co-localized with antigen presentation
molecules (Ii, HLA proteins, membrane and lysosomal proteins),
and those that must be targeted to the endo/lysosome (cytosolic
and nuclear proteins). These findings are in agreement with coarse
analysis comparing thymic and splenic APC in the mouse, which
found no significant differences in class II MHC-bound peptides
[16]. These common endogenous epitopes may therefore contain
sequences favorably suited for stabilization of the T cell synapse
[8,9].
Here we identified a self-antigen repertoire presented by T cells
in healthy donors at steady state. As class II MHC expression is
upregulated in patients with autoimmune diseases such as multiple
sclerosis [41], and during chronic viral infections such as HTLV-1
[42], it would be of great interest to isolate and identify the
presented peptide repertoire in T cells derived from these
individuals. Class II presentation by these cells can lead to
antigen-specific T cell activation, which may contribute to disease
pathogenesis [19,20,21]. Further work must be done to identify
changes in antigen presentation by T cells in chronic disease states
and to determine the extent to which any changes in peptide
repertoire contribute to CD4+ T cell regulation.
Supporting Information
Figure S1 Specificity of peptides eluted from Tu36-
bound beads (black) as compared to isotype control
(red) with MALDI-TOF analysis. EBV lysate (0.7 g wet cell
mass total) was divided and each fraction was subjected to IP,
elution, and mass spectrometry in parallel.
(TIF)
Table S1 List of Peptides identified in the T cell
samples or in the B cell samples from Donor 1.
(XLS)
Table S2 Abundant epitopes identified in both the T cell
and the B cell peptide preparations from Donor 1.
(XLS)
Table S3 Predicted binding of peptides derived from
the common T cell and B cell proteome of Donor 1.Weak
binding peptides, in light blue, are classified as those with a
Table 3. Self-peptides identified in two donors with unique class II MHC expression.
Protein name Donor 1 core peptide Donor 2 core peptide
40S ribosomal protein KITAFVPNDGCLNFIEEN FSGVYKKLTGKDVNFE.F
4F2 cell-surface antigen heavy chain RIGDLQAFQGHGAGN LKGRLDYLSSLKVKGLVL
Apolipoprotein B-100 QILPWEQNEQVKNFVASH LSASYKADTVAKVQGV
TGKIDFLNNYALF KIEGNLIFDPNNYLPKE
VYQGAIRQIDDIDVRFQK
ATP-binding cassette sub-family A member 1 GEKYAGNYSGGNKRKLS HNVLFDMLTVEEHIWFYAR
Beta-2-microglobulin RTPKIQVYSRHPAENG KIQVYSRHPAENGKSNF
KSNFLNCYVSGFHPS
Calreticulin YSPDPSIYAYDNFG CGGGYVKLFPNSLDQT
Cytochrome P450 AGGPVSVYDASKALTFRMAAR HAFLPFSGGSRNCIG
Formin-2 EELGARTPRVGGSAHL EELGARTPRVGGSAHL
Glutathione S-transferase P QDGDLTLYQSNTILRH GKDDYVKALPGQLKPFET
Glyceraldehyde-3-phosphate dehydrogenase ENGKLVINGNPITI FHGTVKAENGKLVINGN
KYDNSLKIISNASCTTN KYDNSLKIISNASCTTNC
EGPLKGILGYTEHQVVSS THSSTFDAGAGIALNDHF
HLA class II histocompatibility antigen, DR alpha chain EFGRFASFEAG EFGRFASFEAQGALANI
Leucyl-cystinyl aminopeptidase IRDEQYTALSNMPKKSSV TDKGWSFLLGKYI
L-lactate dehydrogenase A chain SNPVDILTYVAWKISGFP NVNIFKFIIPNVVKYSPNC
Phosphoglycerate kinase 1 CGPESSKKYAEAVTRAKQI PERPFLAILGGAKVADKI
Proactivator polypeptide EVVAPFMANIPLLLYPQDGPRS YLPVILDIIKGEMSRPGE
Protein disulfide-isomerase A6 GFPTIKIFGSNKNRPED DIDLSDVELDDLGKDEL
Semaphorin-4D NLPDKTLQFVKDHPLMDDS YIRVLQPLSATSLY
Syntenin-1 LNEEEIRANVAVVSGAPL NPAILSEASAPIPHD
Peptides with identical core sequences isolated from both donor 1 and donor 2 are indicated in bold.
doi:10.1371/journal.pone.0029805.t003
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predicted affinity of less than 500 nM. Strong binding peptides, in
yellow, are those classified as having a predicted affinity of less
than 50 nM.
(XLS)
Table S4 List of peptides identified in the T cell
samples or in the B cell samples from Donor 2.
(XLS)
Table S5 Non-self peptides identified during protein
elution, for both donors.
(XLS)
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